Contributions
Abstract: EP749
Type: E-Poster Presentation
Session title: Gene therapy, cellular immunotherapy and vaccination - Clinical
Background
The Bispecific T-cell engager (BiTE) Blinatumomab and the CD19-specific Chimeric Antigen Receptor (CAR) T-cell products Axicabtagene-Ciloleucel and Tisagenlecleucel are approved Immunotherapies for relapsed and refractory B-cell neoplasms. However, they are accompanied by potentially lethal T-cell associated immune related adverse events that significantly differ from toxicities known from chemotherapy or even checkpoint blockade. Patients require comprehensive monitoring and a well educated interdisciplinary team of health care professionals.
Aims
To support the optimal management of these patients, we developed the interactive smartphone application “myTcell”, which guides and educates physicians in the assessment and treatment of CAR & BiTE related toxicities.
Methods
We initiated a multi step content development process with an extensive literature research of toxicity guidelines consented by the ASTCT, EBMT and NCCN as well as of officially released drug information. Findings were translated into an information platform with diagnostic and therapeutic recommendations as well as algorithms for interactive toxicity grading tools. A prototype is currently being validated at three Geman treatment centers before becoming available in Europe. App development has been funded through educational grants by Celgene, Gilead Sciences and Novartis.
Results
“myTcell” guides disease and product specific in a step by step process through the clinical workflow of cell therapy including indication, leukapheresis, bridging therapy and application of CAR T cells and BiTEs. Upon entering relevant clinical data for grading of CRS, ICANS and HLH interactive tools display toxicity grade or likelihood of toxicity as well as grade-specific management recommendations. Further, “myTcell” assists with the diagnosis and treatment of so far underreported adverse events such as pancytopenia. Besides, “myTcell” includes an overview of the key literature and most recent publications in the field of CAR T-cells and BiTEs.
Conclusion
“myTcell” has the potential to become a highly usable smartphone app supporting the application of T-cell recruiting immunotherapies and the education of health care professionals. Thus, “myTcell” can increase guideline adherence, accelerate the broader and safer application of CARs and BiTEs and ultimately improve patient outcomes.
Keyword(s): Bispecific, CAR-T, Diffuse large B cell lymphoma, Toxicity
Abstract: EP749
Type: E-Poster Presentation
Session title: Gene therapy, cellular immunotherapy and vaccination - Clinical
Background
The Bispecific T-cell engager (BiTE) Blinatumomab and the CD19-specific Chimeric Antigen Receptor (CAR) T-cell products Axicabtagene-Ciloleucel and Tisagenlecleucel are approved Immunotherapies for relapsed and refractory B-cell neoplasms. However, they are accompanied by potentially lethal T-cell associated immune related adverse events that significantly differ from toxicities known from chemotherapy or even checkpoint blockade. Patients require comprehensive monitoring and a well educated interdisciplinary team of health care professionals.
Aims
To support the optimal management of these patients, we developed the interactive smartphone application “myTcell”, which guides and educates physicians in the assessment and treatment of CAR & BiTE related toxicities.
Methods
We initiated a multi step content development process with an extensive literature research of toxicity guidelines consented by the ASTCT, EBMT and NCCN as well as of officially released drug information. Findings were translated into an information platform with diagnostic and therapeutic recommendations as well as algorithms for interactive toxicity grading tools. A prototype is currently being validated at three Geman treatment centers before becoming available in Europe. App development has been funded through educational grants by Celgene, Gilead Sciences and Novartis.
Results
“myTcell” guides disease and product specific in a step by step process through the clinical workflow of cell therapy including indication, leukapheresis, bridging therapy and application of CAR T cells and BiTEs. Upon entering relevant clinical data for grading of CRS, ICANS and HLH interactive tools display toxicity grade or likelihood of toxicity as well as grade-specific management recommendations. Further, “myTcell” assists with the diagnosis and treatment of so far underreported adverse events such as pancytopenia. Besides, “myTcell” includes an overview of the key literature and most recent publications in the field of CAR T-cells and BiTEs.
Conclusion
“myTcell” has the potential to become a highly usable smartphone app supporting the application of T-cell recruiting immunotherapies and the education of health care professionals. Thus, “myTcell” can increase guideline adherence, accelerate the broader and safer application of CARs and BiTEs and ultimately improve patient outcomes.
Keyword(s): Bispecific, CAR-T, Diffuse large B cell lymphoma, Toxicity